Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | PI4KA | P42356 | 1/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 4/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | PNP | P00491 | 2/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.43 |
| ▸ | ACP1 | P24666 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16044462 | 0.84 | MET (0.46) | METCYP11B1CYP11B2 | |
| SCHEMBL979313 | 0.78 | MET (0.45) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL24265723 | 0.77 | CYP11B1 (0.53) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL978389 | 0.74 | ADORA2A (0.43) | ADORA2ASMN1; SMN2 | |
| SCHEMBL15470931 | 0.73 | CYP11B1 (0.41) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL30586354 | 0.69 | YTHDC1 (0.65) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL7216047 | 0.68 | CYP11B1 (0.53) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL30586358 | 0.68 | ADORA2A (0.68) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL782938 | 0.68 | YTHDC1 (0.53) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL28290149 | 0.68 | CYP11B1 (0.53) | ADORA2API4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766899-B2 | Methods for preparing substituted imidazo[4,5-b]pyrazines | CYTOKINETICS, INCORPORATED (US) | 2020-09-08 | — | — | US | disclosed |
| US-20140303366-A1 | Certain 1H-Imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-Imidazo[4,5-b]pyrazin-2-ols and Methods for Their Use | CYTOKINETICS, INCORPORATED | 2014-10-09 | — | — | US | disclosed |
| US-8716291-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use | CYTOKINETICS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130053389-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2013-02-28 | — | — | US | disclosed |
| US-8299248-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use | CYTOKINETICS, INCORPORATED (US) | 2012-10-30 | — | — | US | disclosed |
| US-8293761-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-7956056-B2 | Certain 1H-imidazo[4,5-B]pyrazin-2(3H)-ones and 1H-imidazo[4,5-B]pyrazin-2-ols, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20110014212-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INCORPORATED | 2011-01-20 | — | — | US | disclosed |
| US-20100210645-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100093741-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2010-04-15 | — | — | US | disclosed |
| US-7598248-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210645-A1 | Certain Chemical Entities, Compositions and Methods | TNNC1, TNNI3, TNNT2 | ADORA2A 4328/4885PI4KA 3534/4885PI4K2B 4295/4885 |
| US-20130053389-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | TNNI3, TNNT2, TNNC1 | ADORA2A 2559/4885PI4KA 4671/4885PI4K2B 4768/4885 |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | TNNC1, TNNI3, TNNT2 | ADORA2A 4328/4885PI4KA 3534/4885PI4K2B 4295/4885 |
| US-10766899-B2 | Methods for preparing substituted imidazo[4,5-b]pyrazines | CYP4B1, CYP3A5, CYP4F12 | ADORA2A 1580/4885PI4KA 1586/4885PI4K2B 843/4885 |
| US-20140303366-A1 | Certain 1H-Imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-Imidazo[4,5-b]pyrazin-2-ols and Methods for Their Use | TNNI3, TNNT2, TNNC1 | ADORA2A 3901/4885PI4KA 3382/4885PI4K2B 2511/4885 |
| US-20100093741-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | TNNC1, TNNI3, TNNT2 | ADORA2A 4328/4885PI4KA 3534/4885PI4K2B 4295/4885 |
| US-20110014212-A1 | Certain Chemical Entities, Compositions and Methods | TNNI3, TNNT2, TNNC1 | ADORA2A 2559/4885PI4KA 4671/4885PI4K2B 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.